» Articles » PMID: 37063871

Characterisation of the Pro-inflammatory Cytokine Signature in Severe COVID-19

Abstract

Clinical outcomes from infection with SARS-CoV-2, the cause of the COVID-19 pandemic, are remarkably variable ranging from asymptomatic infection to severe pneumonia and death. One of the key drivers of this variability is differing trajectories in the immune response to SARS-CoV-2 infection. Many studies have noted markedly elevated cytokine levels in severe COVID-19, although results vary by cohort, cytokine studied and sensitivity of assay used. We assessed the immune response in acute COVID-19 by measuring 20 inflammatory markers in 118 unvaccinated patients with acute COVID-19 (median age: 70, IQR: 58-79 years; 48.3% female) recruited during the first year of the pandemic and 44 SARS-CoV-2 naïve healthy controls. Acute COVID-19 was associated with marked elevations in nearly all pro-inflammatory markers, whilst eleven markers (namely IL-1β, IL-2, IL-6, IL-10, IL-18, IL-23, IL-33, TNF-α, IP-10, G-CSF and YKL-40) were associated with disease severity. We observed significant correlations between nearly all markers elevated in those infected with SARS-CoV-2 consistent with widespread immune dysregulation. Principal component analysis highlighted a pro-inflammatory cytokine signature (with strongest contributions from IL-1β, IL-2, IL-6, IL-10, IL-33, G-CSF, TNF-α and IP-10) which was independently associated with severe COVID-19 (aOR: 1.40, 1.11-1.76, p=0.005), invasive mechanical ventilation (aOR: 1.61, 1.19-2.20, p=0.001) and mortality (aOR 1.57, 1.06-2.32, p = 0.02). Our findings demonstrate elevated cytokines and widespread immune dysregulation in severe COVID-19, adding further evidence for the role of a pro-inflammatory cytokine signature in severe and critical COVID-19.

Citing Articles

Lipoxin A levels correlate with severity in a Spanish COVID-19 cohort: potential use of endogenous pro-resolving mediators as biomarkers.

Sanchez-Garcia S, Jaen R, Lozano-Rodriguez R, Avendano-Ortiz J, Pascual-Iglesias A, Hurtado-Navarro L Front Immunol. 2025; 15:1509188.

PMID: 39916956 PMC: 11798798. DOI: 10.3389/fimmu.2024.1509188.


Prognostic Value of Baseline Serum Pro-Inflammatory Cytokines in Severe Multisystem Inflammatory Syndrome in Children.

Bartha-Tatar A, Sinkovits G, Schnur J, Maraczi V, David M, Zsigmond B J Clin Med. 2024; 13(23).

PMID: 39685637 PMC: 11642126. DOI: 10.3390/jcm13237177.


Cytokine Storm in COVID-19: Exploring IL-6 Signaling and Cytokine-Microbiome Interactions as Emerging Therapeutic Approaches.

Paranga T, Mitu I, Pavel-Tanasa M, Rosu M, Miftode I, Constantinescu D Int J Mol Sci. 2024; 25(21).

PMID: 39518964 PMC: 11547016. DOI: 10.3390/ijms252111411.


Circulating Interleukin-17A is associated with executive function in middle aged adults with and without type 2 diabetes.

Morrison L, Dyer A, Dolphin H, Batten I, Reddy C, Widdowson M Brain Behav Immun Health. 2024; 41:100862.

PMID: 39350951 PMC: 11440310. DOI: 10.1016/j.bbih.2024.100862.


Performance of plasma p-tau217 for the detection of amyloid-β positivity in a memory clinic cohort using an electrochemiluminescence immunoassay.

Dyer A, Dolphin H, OConnor A, Morrison L, Sedgwick G, Young C Alzheimers Res Ther. 2024; 16(1):186.

PMID: 39160628 PMC: 11331802. DOI: 10.1186/s13195-024-01555-z.


References
1.
Gordon A, Mouncey P, Al-Beidh F, Rowan K, Nichol A, Arabi Y . Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19. N Engl J Med. 2021; 384(16):1491-1502. PMC: 7953461. DOI: 10.1056/NEJMoa2100433. View

2.
Messing M, Sekhon M, Hughes M, Stukas S, Hoiland R, Cooper J . Prognostic peripheral blood biomarkers at ICU admission predict COVID-19 clinical outcomes. Front Immunol. 2022; 13:1010216. PMC: 9703061. DOI: 10.3389/fimmu.2022.1010216. View

3.
Han H, Ma Q, Li C, Liu R, Zhao L, Wang W . Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors. Emerg Microbes Infect. 2020; 9(1):1123-1130. PMC: 7473317. DOI: 10.1080/22221751.2020.1770129. View

4.
Asano T, Boisson B, Onodi F, Matuozzo D, Moncada-Velez M, Maglorius Renkilaraj M . X-linked recessive TLR7 deficiency in ~1% of men under 60 years old with life-threatening COVID-19. Sci Immunol. 2021; 6(62). PMC: 8532080. DOI: 10.1126/sciimmunol.abl4348. View

5.
McElvaney O, Hobbs B, Qiao D, McElvaney O, Moll M, McEvoy N . A linear prognostic score based on the ratio of interleukin-6 to interleukin-10 predicts outcomes in COVID-19. EBioMedicine. 2020; 61:103026. PMC: 7543971. DOI: 10.1016/j.ebiom.2020.103026. View